Abstract
Some trials fail because the experimental treatment proves to be no different than a control or standard intervention. Others fail because of unacceptable side effects. In this issue of the Journal, an article by Egan et al.1 and a letter to the editor by Henley et al.2 describe a third reason for failure — a treatment worsens the target symptoms. The therapeutic intervention of lowering brain amyloid-beta (Aβ) peptide levels to treat patients with Alzheimer’s disease is based on a conceptual model in which accumulation of Aβ is causally related to cognitive decline. The model is rooted in the inseparability . . .

This publication has 10 references indexed in Scilit: